| Literature DB >> 30486226 |
Adrian Post1, Akin Ozyilmaz2, Ralf Westerhuis3, Karin J R Ipema4, Stephan J L Bakker5, Casper F M Franssen6.
Abstract
To prevent protein energy malnutrition (PEM) and accumulation of waste products, dialysis patients require diet adjustments. Dietary intake assessed by self-reported intakes often provides biased information and standard 24-h urinary excretion is inapplicable in dialysis patients. We aimed to assess dietary intake via a complementary, less biased biomarker method, and to compare this to dietary diaries. Additionally, we investigated the prospective association of creatinine excretion rate (CER) reflecting muscle mass with mortality. Complete intradialytic dialysate and interdialytic urinary collections were used to calculate 24-h excretion of protein, sodium, potassium, phosphate and creatinine in 42 chronic dialysis patients and compared with protein, sodium, potassium, and phosphate intake assessed by 5-day dietary diaries. Cox regression analyses were employed to investigate associations of CER with mortality. Mean age was 64 ± 13 years and 52% were male. Complementary biomarker assessed (CBA) and dietary assessed (DA) protein intake were significantly correlated (r = 0.610; p < 0.001), but there was a constant bias, as dietary diaries overestimated protein intake in most patients. Correlations were found between CBA and DA sodium intake (r = 0.297; p = 0.056), potassium intake (r = 0.312; p = 0.047) and phosphate uptake/intake (r = 0.409; p = 0.008). However, Bland-Altman analysis showed significant proportional bias. During a median follow-up of 26.6 (25.3⁻31.5) months, nine dialysis patients (23%) died. CER was independently and inversely associated with survival (HR: 0.59 (0.42⁻0.84); p = 0.003). Excretion measurements may be a more reliable assessment of dietary intake in dialysis patients, as this method is relatively free from biases known to exist for self-reported intakes. CER seems to be a promising tool for monitoring PEM.Entities:
Keywords: creatinine; dialysis; dietary diaries; excretion; phosphate; potassium; protein; protein energy malnutrition; sodium
Mesh:
Substances:
Year: 2018 PMID: 30486226 PMCID: PMC6316271 DOI: 10.3390/nu10121827
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 5.717
Patient characteristics.
| Baseline Characteristics | Average/Number | Range |
|---|---|---|
|
| ||
| Age, years | 64 ± 13 | 25–86 |
| Gender, | 22 (52) | |
| Race, | 39 (93) | |
|
| ||
| Dialysis sessions, n (%) | ||
| 2 sessions per week | 1 (2) | |
| 3 sessions per week | 41 (98) | |
| Hours per dialysis, n (%) | ||
| 3 to 3.5 h | 6 (14) | |
| 4 h | 34 (81) | |
| 4.5 to 5 h | 2 (5) | |
| Residual diuresis, | 22 (52) | |
| Urinary volume, L | 0.84 ± 0.57 | 0.14–2.39 |
| Dialysis vintage, months | 14 (6–45) | 2–202 |
| Ultrafiltration volume, ml | 1926 ± 921 | 1425–2725 |
|
| ||
| Target body weight, kg | 80.2 ± 15.6 | 72.5–89.9 |
| Interdialytic weight gain, kg | 1.17 ± 1.12 | −1.7–4.4 |
| Height, m | 1.75 ± 0.09 | 1.66–1.83 |
| BMI, kg/m2 | 25.6 ± 4.3 | 22.7–28.8 |
| BSA, m2 | 1.93 ± 0.21 | 1.82–2.06 |
|
| ||
| Hypertension, | 28 (67) | |
| Diabetes, | 12 (29) | |
| Cardiovascular disease, | 18 (43) | |
|
| ||
| Use of phosphate binders, | 21 (50) | |
| Sevelamer | 15 (36) | |
| Calciumcarbonate or lanthanumcarbonate | 11 (26) | |
| Calciumacetate and magnesiumcarbonate (OsvaRen) | 6 (14) | |
| Use of potassium binders, | 4 (10) |
* Used potassium binder was calcium polystyrene sulfonate. Abbreviations: BMI, body mass index; BSA, body surface area.
Clinical and laboratory parameters before and after dialysis.
| Variable | Before Dialysis | After Dialysis | |
|---|---|---|---|
| Clinical | |||
| Systolic blood pressure (mmHg) | 147 ± 21 | 138 ± 27 | 0.012 |
| Diastolic blood pressure, (mmHg) | 69 ± 12 | 67 ± 11 | 0.163 |
| Pulse, min−1 | 74 ± 14 | 73 ± 12 | 0.631 |
| Body weight, kg | 80.0 ± 16.0 | 78.7 ± 16.0 | < 0.001 |
| Laboratory | |||
| Hemoglobin (mmol/L) | 6.9 ± 0.7 | 7.4 ± 1.0 | 0.001 |
| Hematocrit | 0.34 ± 0.04 | 0.36 ± 0.04 | 0.012 |
| Sodium (mmol/L) | 138 ± 3 | 139 ± 2 | 0.023 |
| Potassium (mmol/L) | 4.9 ± 0.5 | 3.5 ± 0.4 | < 0.001 |
| Phosphate (mmol/L) | 1.6 ± 0.6 | 0.8 ± 0.2 | < 0.001 |
| Albumin (g/L) | 40 ± 5 | 43 ± 4 | < 0.001 |
| Urea (mmol/L) | 20 ± 5 | 6 ± 2 | < 0.001 |
| Creatinine (µmol/L) | 707 ± 196 | 265 ± 94 | < 0.001 |
Mean values of complementary biomarker assessed (CBA) intakes and dietary assessed (DA) intakes of protein, sodium, potassium and phosphate.
| Variable | CBA Intake * | DA Intake | |
|---|---|---|---|
| Protein (g/24 h) | 63 ± 19 | 71 ± 19 | 0.003 |
| Sodium (mg/24 h) | 4035 ± 2316 | 2123 ± 616 | < 0.001 |
| Potassium (mg/24 h) | 2041 ± 907 | 2445 ± 568 | 0.008 |
| Phosphate (mg/24 h) | 1427 ± 637 | 1221 ± 276 | 0.029 |
* = uptake in the case of phosphate.
Figure 1(a) Comparison of complementary biomarker assessed (CBA) protein intake and diary assessed (DA) protein intake (r = 0.610; p < 0.001); (b) Bland-Altman plot for CBA protein intake and DA protein intake, showing constant bias (p = 0.003), and no proportional bias (r = −0.023; p = 0.888).
Figure 2(a) Comparison of complementary biomarker assessed (CBA) sodium intake and diary assessed (DA) sodium intake (r = 0.297; p = 0.056); (b) Bland-Altman plot for CBA sodium intake and DA sodium intake, with significant proportional bias (r = 0.887; p < 0.001).
Figure 3(a) Comparison of complementary biomarker assessed (CBA) potassium intake and diary assessed (DA) potassium intake (r=0.312; p = 0.047); (b) Bland-Altman plot for CBA potassium intake and DA potassium intake, with significant proportional bias (r = 0.446; p = 0.003).
Figure 4(a) Comparison of complementary biomarker assessed (UBA) phosphate uptake and diary assessed (DA) phosphate intake (r = 0.409; p = 0.008); (b) Bland-Altman plot for CBA phosphate uptake and DA phosphate intake, with significant proportional bias (r = 0.710; p < 0.001).
Figure 5(a) Kaplan-Meier curves for sex-stratified tertiles of creatinine excretion rate (CER) and (b) creatinine excretion rate, indexed to height2 (CERH).
Cox regression analyses for prediction of patient mortality based on excretion of creatinine excretion rate (CER) and creatinine excretion indexed to height2 (CERH).
| Model | CER | CERH | ||
|---|---|---|---|---|
| HR (95% CI) | HR (95% CI) | |||
| 1 | 0.59 (0.42–0.84) | 0.003 | 0.13 (0.04–0.45) | 0.001 |
| 2 | 0.50 (0.29–0.83) | 0.007 | 0.14 (0.03–0.61) | 0.009 |
| 3 | 0.47 (0.28–0.79) | 0.005 | 0.12 (0.03–0.56) | 0.007 |
| 4 | 0.49 (0.29–0.82) | 0.007 | 0.14 (0.03–0.62) | 0.010 |
| 5 | 0.50 (0.30–0.82) | 0.007 | 0.14 (0.03–0.61) | 0.009 |
Model 1, crude model; model 2, adjusted for age and sex; model 3, as model 2, additionally adjusted BMI; model 4, as model 2, additionally adjusted for BSA; model 5, as model 2, additionally adjusted for systolic blood pressure.